Screening for hepatocellular carcinoma

Gastroenterology and Hepatology

Volumn 4, Issue 3, 2008, Pages 201-208

  Singal, Amit ^a   Marrero, Jorge A ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Multidisciplinary Liver Tumor Clinic

Author keywords

Detection; Diagnosis; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Liver cancer

Indexed keywords

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHRONIC HEPATITIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; ECONOMIC ASPECT; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICAL TECHNOLOGY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; ULTRASOUND; WORLD HEALTH ORGANIZATION;

EID: 42549156520     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst. 1980;64:1263-1272.
2. Smith RA. Screening fundamentals. J Natl Cancer Inst Monogr. 1997:15-19.
3. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273-278.
4. Meissner HI, Smith RA, Rimer BK, Wilson KM, Rakowski W, et al. Promoting cancer screening: learning from experience. Cancer. 2004;101:1107-1117.
5. Espey DK, Wu XC, Swan J, Wiggins C, Jim MA, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007;110:2119-2152.
6. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271-285.
7. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191-211, v.
8. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27-S34.
9. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817-823.
10. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, et al. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A. 2002;99:15584-15589.
11. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F, EUROCARE Working Group. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol. 2007;102:1661-1670; quiz 1660, 1671.
12. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33:62-65.
13. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129-1133.
14. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989;2:1006-1008.
15. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.
16. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001;5:87-107, vi.
17. Deugnier Y, Turlin B. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16:491-494.
18. Farinati F, Floreani A, De Maria N, Fagiuoli S, Naccarato R, Chiaramonte M. Hepatocellular carcinoma in primary biliary cirrhosis. J Hepatol. 1994;21:315-316.
19. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349-1354.
20. Nishiyama R, Kanai T, Abe J, Hara R, Watahiki Y, et al. Hepatocellular carcinoma associated with autoimmune hepatitis. J Hepatobiliary Pancreat Surg. 2004;11:215-219.
21. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652-659.
22. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50.
23. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
24. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155:323-331.
25. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460-468.
26. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer. 2000;85:498-502.
27. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
28. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003;37:520-527.
29. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
30. Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:991-1008.
31. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
32. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101:422-434.
33. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679-690.
34. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159-1172.
35. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol. 1999;94:2224-2229.
36. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 2005;11:281-289.
37. Srinivas PR, Kramer BS, Srivastava S. Trends in biomarker research for cancer detection. Lancet Oncol. 2001;2:698-704.
38. Colli A, Fraquelli M, Conte D. Alpha-fetoprotein and hepatocellular carcinoma. Am J Gastroenterol. 2006;101:1939; author reply 1940-1931.
39. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570-575.
40. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003;139:46-50.
41. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43:434-441.
42. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995;22:432-438.
43. Sangiovanni A, Colombo E, Radaelli F, Bortoli A, Bovo G, et al. Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. Am J Gastroenterol. 2001;96:1575-1580.
44. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32:842-846.
45. Ono M, Ohta H, Ohhira M, Sekiya C, Namiki M. Measurement of immunoreactive prothrombin precursor and vitamin-K-dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumour Biol. 1990;11:319-326.
46. Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology. 2002;49:235-238.
47. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000;95:1036-1040.
48. Izuno K, Fujiyama S, Yamasaki K, Sato M, Sato T. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology. 1995;42:387-393.
49. Shimauchi Y, Tanaka M, Kuromatsu R, Ogata R, Tateishi Y, et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep. 2000;7:249-256.
50. Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology. 1990;99:508-518.
51. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 1993;328:1802-1806.
52. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology. 1995;22:802-807.
53. Wang SS, Lu RH, Lee FY, Chao Y, Huang YS, et al. Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol. 1996;25:166-171.
54. Shokar NK, Vernon SW, Weller SC. Cancer and colorectal cancer: knowledge, beliefs, and screening preferences of a diverse patient population. Fam Med. 2005;37:341-347.
55. Yang B, Zhang B, Xu Y, Wang W, Shen Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol. 1997;123:357-360.
56. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-422.
57. Peng YC, Chan CS, Chen GH. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepatogastroenterology. 1999;46:3208-3211.
58. Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, et al. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology. 2000;47:1654-1658.
59. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747-1753.
60. Lee HS, Chung YH, Kim CY. Specificities of serum alpha-fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma. Hepatology. 1991;14:68-72.
61. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology. 2002;36:410-417.
62. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol. 1994;20:65-71.
63. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61-66.
64. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, et al. Surveillance program of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251-259.
65. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol. 2001;16:553-559.
66. Cottone M, Turri M, Caltagirone M, Maringhini A, Sciarrino E, et al. Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alfafetoprotein: a prospective study. Hepatogastroenterology. 1988;35:101-103.
67. Kobayashi K, Sugimoto T, Makino H, Kumagai M, Unoura M, et al. Screening methods for early detection of hepatocellular carcinoma. Hepatology. 1985;5:1100-1105.
68. Sheu JC, Sung JL, Chen DS, Lai MY, Wang TH, et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer. 1985;56:660-666.
69. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1990;12:680-687.
70. Van Thiel DH, Yong S, Li SD, Kennedy M, Brems J. The development of de novo hepatocellular carcinoma in patients on a liver transplant list: frequency, size, and assessment of current screening methods. Liver Transpl. 2004;10:631-637.
71. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005-1014.
72. Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood. 2003;102:78-82.
73. Henrion J, Libon E, De Maeght S, Schapira M, Ghilain JM, et al. Surveillance for hepatocellular carcinoma: compliance and results according to the aetiology of cirrhosis in a cohort of 141 patients. Acta Gastroenterol Belg. 2000;63:5-9.
74. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer. 1996;78:977-985.
75. Tradati F, Colombo M, Mannucci PM, Rumi MG, De Fazio C, et al. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood. 1998;91:1173-1177.
76. Imberti D, Fornari F, Sbolli G, Buscarini E, Squassante L, Buscarini L. Hepatocellular carcinoma in liver cirrhosis. A prospective study. Scand J Gastroenterol. 1993;28:540-544.
77. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675-680.
78. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol. 1994;21:1029-1034.
79. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131-136.
80. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25:754-758.
81. Caturelli E, Bartolucci F, Biasini E, Vigliotti ML, Andriulli A, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol. 2002;97:397-405.
82. Iavarone M, Lampertico P, Ronchi G, Del Ninno E, Zanella A, Colombo M. A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis. J Viral Hepat. 2003;10:423-426.